当前位置: 首页 >> 检索结果
共有 20035 条符合本次的查询结果, 用时 2.3621096 秒

281. Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.

作者: Duvuru Geetha.;Christian Pagnoux.;Sebastian E Sattui.;Peter A Merkel.;Maria Weiner.;Juliana Draibe.;Stanislas Faguer.;Sarah Bray.;Rachel E Gurlin.;Monica Balcells-Oliver.;Annette Bruchfeld.;David R Jayne.; .
来源: Rheumatology (Oxford). 2025年
To evaluate the efficacy and safety of avacopan in patients aged ≥65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide.

282. "I still can't forget those words": mixed methods study of the persisting impact on patients reporting psychosomatic and psychiatric misdiagnoses.

作者: Melanie Sloan.;Michael Bosley.;Caroline Gordon.;Thomas A Pollak.;Farhana Mann.;Efthalia Massou.;Stephen Morris.;Lynn Holloway.;Rupert Harwood.;Kate Middleton.;Wendy Diment.;James Brimicombe.;Elliott Lever.;Lucy Calderwood.;Ellie Dalby.;Elaine Dunbar.;David D'Cruz.;Felix Naughton.
来源: Rheumatology (Oxford). 2025年
This research aimed to improve understanding of persisting impacts of patient-reported psychosomatic and psychiatric misdiagnoses on patients with systemic autoimmune rheumatic diseases (SARDs).

283. Effect of intra-articular corticosteroid injections for osteoarthritis on the subsequent use of pain medications: a UK CPRD cohort study.

作者: Samuel Hawley.;Albert Prats-Uribe.;Gulraj S Matharu.;Antonella Delmestri.;Daniel Prieto-Alhambra.;Andrew Judge.;Michael R Whitehouse.
来源: Rheumatology (Oxford). 2025年
To estimate the effect of intra-articular corticosteroid injection (IACI) for osteoarthritis on longer-term incidence of pain medications.

284. Effects of early steroid reduction in initial combination therapy for Kawasaki disease.

作者: Teruyoshi Shimoyama.;Ryuichi Nakagawa.;Saori Amano.;Haruna Yokoyama.;Mari Okada.;Tomohiro Udagawa.;Natsuko Suzuki.;Susumu Hosokawa.;Masayuki Nagasawa.
来源: Rheumatology (Oxford). 2025年
In recent years, the use of steroids as an initial adjunctive therapy for patients with Kawasaki disease (kDa) at high risk of being unresponsive to intravenous immunoglobulin (IVIG) has shown promising outcomes. However, the optimal duration and tapering method of steroid therapy have not been thoroughly investigated. While the RAISE study, which followed the most prominent protocol in Japan, tapers and discontinues steroids for >15 days, our institution reduces and discontinues steroids over six days once inflammation is adequately controlled. In this study, we aimed to determine the effects of our protocol of steroid tapering in initial combination therapy for kDa.

285. Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry.

作者: Marius L Smits.;Casper Webers.;Harald E Vonkeman.;Astrid van Tubergen.
来源: Rheumatology (Oxford). 2025年
To explore (1) the prevalence of difficult-to-manage axial spondyloarthritis (D2M axSpA) in clinical practice according to the Assessment of SpondyloArthritis international Society (ASAS) definition, (2) specific components of this definition contributing most to its fulfilment, and (3) associated patient characteristics.

286. Ultrasound: a useful tool for diagnosing tibial stress fractures.

作者: Andrés Ponce.;Pilar Peris.;Beatriz Frade-Sosa.;Claudia Arango.;Cynthia Rojas.;José A Gómez-Puerta.
来源: Rheumatology (Oxford). 2025年

287. Challenges in the diagnosis and management of psoriatic arthritis in people of colour.

作者: Ade Adebajo.;Mary Sommerlad.;Laura Savage.;Philip Helliwell.
来源: Rheumatology (Oxford). 2025年

288. Comment on: Acute respiratory distress syndrome after emapalumab treatment in a child with severe Still's disease and lung involvement: a case report.

作者: Vivian E Saper.;Ruud H J Verstegen.
来源: Rheumatology (Oxford). 2025年

289. Autoantibodies and malignancy risk in patients with vesiculobullous dermatomyositis.

作者: Sophie Breedveld.;Joshua Prenner.;Grant Zhao.;Jennifer L Shastry.;Cuong V Nguyen.
来源: Rheumatology (Oxford). 2025年

290. Comment on: Associations between loneliness, disease activity and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients: reply.

作者: Sofie Bech Vestergaard.;Bente Appel Esbensen.;Julie Midtgaard.;Pernille Fevejle Cromhout.;Mette Aadahl.;Bente Glintborg.;Annette de Thurah.
来源: Rheumatology (Oxford). 2025年

291. Identified genetic locus for longitudinal disease activity in adults with systemic lupus erythematosus.

作者: Melissa C Misztal.;Fangming Liao.;Nick Gold.;Jingjing Cao.;Dafna D Gladman.;Zahi Touma.;Joan Wither.;Richard Cook.;Murray Urowitz.;Linda T Hiraki.
来源: Rheumatology (Oxford). 2025年
Genetics significantly impact systemic lupus erythematosus (SLE) risk, disease manifestations, and damage. Our aim was to identify genetic risk loci for disease activity burden over time.

292. Publisher Correction: An international perspective on the future of systemic sclerosis research.

作者: David J Abraham.;Carol M Black.;Christopher P Denton.;Jörg H W Distler.;Robyn Domsic.;Carol Feghali-Bostwick.;Pravitt Gourh.;Monique Hinchcliff.;Fred Kolling.;Masataka Kuwana.;Robert Lafyatis.;Ulf Landegren.;J Matthew Mahoney.;Javier Martin.;Marco Matucci-Cerinic.;Zsuzsanna H McMahan.;Ana L Mora.;Luc Mouthon.;Marlene Rabinovitch.;Mauricio Rojas.;Kristofer Rubin.;Maria Trojanowska.;John Varga.;Michael L Whitfield.;Armando Gabrielli.;Thomas Krieg.
来源: Nat Rev Rheumatol. 2025年21卷4期249页

293. Joint location matters for TNF inhibitor treatment in PsA.

作者: Holly Webster.
来源: Nat Rev Rheumatol. 2025年21卷4期193页

294. Targeting T cell-activating NETs in uveitis.

作者: Maria Papatriantafyllou.
来源: Nat Rev Rheumatol. 2025年21卷4期191页

295. The same genotype gives rise to a spectrum of disorders.

作者: Qingping Yao.
来源: Lancet Rheumatol. 2025年7卷6期e378-e379页

296. Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study.

作者: Jerome Hadjadj.;Anna Wolfers.;Oleg Borisov.;Derek Hazard.;Ronan Leahy.;Marie Jeanpierre.;Alexandre Belot.;Shahrzad Bakhtiar.;Fabian Hauck.;Pui Y Lee.;Stefano Volpi.;Serena Palmeri.;Vincent Barlogis.;Nathalie Aladjidi.;Georg Ebetsberger-Dachs.;Jerome Avouac.;Fabienne Charbit-Henrion.;Morgane Cheminant.;Jean Donadieu.;Sujal Ghosh.;David P Hoytema van Konijnenburg.;Julia Körholz.;Jacinta Bustamante.;Jeremie Rosain.;Lisa Forbes Satter.;Ingrid Selmeryd.;Georgios Sogkas.;Benedicte Neven.;Frederic Rieux-Laucat.;Stephan Ehl.; .
来源: Lancet Rheumatol. 2025年7卷6期e391-e402页
Suppressor of cytokine signalling 1 (SOCS1) insufficiency is an inborn error of immunity affecting the negative regulation of cytokine and growth factor signalling. We aimed to enhance the understanding of clinical manifestations, disease trajectories, disease penetrance, and the effect of Janus kinase (JAK) inhibition in individuals with SOCS1 insufficiency.

297. Thrombotic microangiopathy as a presentation of anti-synthetase syndrome.

作者: Yu Zuo.;Guming Zou.;Xiaoming Shu.
来源: Lancet Rheumatol. 2025年

298. TASL has a key role in SLE.

作者: Holly Webster.
来源: Nat Rev Rheumatol. 2025年21卷4期192页

299. Is thickened hyaline cartilage on ultrasound a sign of osteoarthritis? A within-person, between-joint pilot study.

作者: Edoardo Cipolletta.;Gianluca Smerilli.;Riccardo Mirza Mashadi.;Peter Mandl.;Emilio Filippucci.
来源: BMC Rheumatol. 2025年9卷1期24页
To determine whether the presence of conventional radiography (CR)-detected osteophytes is associated with focal thickening of the hyaline cartilage by ultrasound (US) in the same area of the metacarpal head in a within-person, between-joint cross-sectional comparison in patients with hand osteoarthritis (HOA).

300. A cohort study in HigAshi-nippon of Pulmonary hyPertensIoN in systEmic SclerosiS (HAPPINESS study): protocol and baseline data for an observational study.

作者: Shuhei Takeyama.;Hironari Hanaoka.;Akiyoshi Hashimoto.;Yusho Ishii.;Yuka Shimizu.;Toshiharu Takeuchi.;Shuhei Shimoyama.;Masataka Kuwana.;Tomoaki Higuchi.;Masaru Yoshimura.;Hiroshi Kataoka.;Yuko Shirota.;Kazufumi Okada.;Yoichi M Ito.;Ryo Hisada.;Kazuro Kamada.;Sho Ishigaki.;Tetsuya Horita.;Tatsuya Atsumi.;Masaru Kato.; .
来源: BMC Rheumatol. 2025年9卷1期25页
Pulmonary hypertension (PH) is the leading cause of death among patients with systemic sclerosis (SSc). Recently, early therapeutic intervention to improve the prognosis was suggested, and the definition of PH was recently revised by lowering the cut-off value of mean pulmonary arterial pressure (mPAP) from ≥ 25 to > 20 mmHg. However, the optimal threshold for therapeutic intervention remains unclear. We aim to evaluate the prognosis of patients with SSc and its relationship with mPAP.
共有 20035 条符合本次的查询结果, 用时 2.3621096 秒